Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

phaValue, Berenberg Bank, Deutsche Bank, Exane BNP Paribas, Morgan Stanley, RBC Capital Markets, Spin-Off Research, Standard & Poor's and UBS) lowered their price targets[15]. At the time of the Proposal Announcement, a significant majority of analysts had price targets at or below the Proposal Price.

A majority of analysts that have released comments on the Tysabri Transaction included at least some commentary expressing uncertainty on Elan's acquisition strategy or track record[16].

Royalty Pharma also believes that the Elan Stock price prior to the Proposal Announcement was, to an extent, inflated by takeover speculation, as supported by the fact that a number of analysts also included at least some commentary mentioning the possibility of Elan being a potential acquisition target[17].

Higher value attributed to the Tysabri Royalty than that implied by the Tysabri TransactionRoyalty Pharma believes that it is offering Elan Shareholders a value for the Tysabri Royalty that is higher than the value implied by the Tysabri Transaction. This is despite the fact that Royalty Pharma would not gain control of Tysabri through an acquisition of Elan, and the fact that the tiered Tysabri Royalty structure allocates more value to Biogen on the lower risk cash flows accruing from Tysabri (the first US$2 billion of annual sales from the drug) and makes the value accruing to Elan more dependent on the higher risk cash flows (the incremental annual sales from the drug above US$2 billion).

The Tysabri Transaction, in which Elan was a willing seller, set an implied value on the residual Tysabri Royalty held by Elan. The implied value of the residual Tysabri Royalty held by Elan depends on the percentage of Elan's economic interest in Tysabri that was acquired by Biogen in the Tysabri Transaction (the "Disposed Tysabri Percentage"). Elan and Biogen have not disclosed what they believe this percentage to be, but it may be estimated on the basis of pr
'/>"/>

SOURCE RP Management, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
6. AVANIR Pharmaceuticals To participate in two conferences in March
7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... MA & Budapest, Hungary (PRWEB) April 30, 2015 ... only web-based electronic lab notebook with integrated protocols ... in providing chemistry software solutions and consulting services ... led to the development of Labguru’s newest feature: ... set of deep domain features for biologists, bio-chemists, ...
(Date:4/30/2015)... Calif. , April 30, 2015  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... on Thursday, May 7, 2015 after the close of ... conference call and webcast on Thursday, May 7, 2015 ... discuss the results and recent corporate developments. ...
(Date:4/30/2015)... 30, 2015 Available in select ... http://www.lespausa.com , Fleur’s introduces CC ... the benefits of makeup, skin care and solar ... cream is designed with specific complexion-correcting pigments to ... complexion and a healthy glow. Far more than ...
(Date:4/30/2015)... California (PRWEB) April 30, 2015 ... 2015 PharmaSUG Annual Conference held in Orlando, ... of Staffing Solutions along with Leslie Kolman, Manager of ... the latest Clinovo news at Booth #17. , ... Annual Conference again this year”, Says Trisha Heredia, Senior ...
Breaking Biology Technology:Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3
... talks are among those that will be presented by ... Laboratory at the American Physical Society meeting, March 10-14, ... Please note that the content of each talk is ... below. All of the research described below was funded ...
... Medco Health,Solutions, Inc. (NYSE: MHS ) announced ... principal amount of 6-1/8 percent senior notes due March,15, ... percent,senior notes due March 15, 2018 in an underwritten ... Securities LLC and Barclays,Capital Inc. are acting as representatives ...
... 14 at 8:00 a.m. PDT ... ... (Nasdaq: HALO ), a biopharmaceutical company developing and,commercializing products targeting the ... December 31, 2007., "Our achievements in 2007 have advanced our partnered ...
Cached Biology Technology:News from the March 2008 American Physical Society Meeting 2News from the March 2008 American Physical Society Meeting 3News from the March 2008 American Physical Society Meeting 4News from the March 2008 American Physical Society Meeting 5Medco Issues $1.5 Billion of Senior Notes 2Medco Issues $1.5 Billion of Senior Notes 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 2Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 4Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 5Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 6Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 7Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 8
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... are improving the taste, appearance and nutritional content of ... grow to $6 billion by 2017, according to a ... (IFT) Annual Meeting & Food Expo in Chicago. ... an immune disorder triggered by the ingestion of gluten ...
... tissue sustains irreparable damage in the wake of a ... and the cardiac muscle contains few stem cells, the ... fibrotic and cannot contract properly. In their search ... been exploring cardiac "patches" that could be transplanted into ...
... to cancer and other diseases, genetic testing, infectious proteins ... topics internationally renowned speakers will tackle at The EMBO ... from 21-24 September 2013. Sir Michael Stratton, Director ... Executive Officer of deCODE Genetics, and Thijn Brummelkamp, Group ...
Cached Biology News:New technologies and ingredients provide better options for gluten-free eating 2A heart of gold 2Anne Glover and Sir Michael Stratton to meet the press at The EMBO Meeting 2013 in Amsterdam 2
... of Class II Biological Safety Cabinets ... to the world's highest safety standards. ... cabinets cannot be adjusted out of ... noise and arm rest ensure safety ...
... recently launched a custom synthesis service ... Thermos siRNA molecules are: Composed ... DNA bases overhang at the 3-terminus ... fully deprotected and ready-to-use. Simply ...
... orbital shaker stands both present ... ergonomic height, and help protect ... welded tubular steel, these heavy-duty ... the weight and minimize the ...
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
Biology Products: